USFDA concludes inspection at Emcure Pharma Gujarat facility without any observation
Pune: Emcure Pharma has announced that the United States Food and Drug Administration (US FDA) has concluded an inspection at the Company’s Gujarat manufacturing facility without any observation.
The surveillance inspection was conducted from October 06, 2025 to October 10, 2025.
"This is to inform you that the United States Food and Drug Administration (“US FDA”) had conducted surveillance inspection of Company’s manufacturing facility located at Survey No. 485 (New), 160/P1 (Old), Kadu, Taluka - Lakhtar, District- Surendranagar, Gujarat - 382775, from October 06, 2025 to October 10, 2025," Emcure stated in a BSE filing.
Read also: Emcure Pharma Gets CDSCO Panel Nod for Phase III Trial of Semaglutide in Chronic Weight Management
Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.
Read also: Emcure Pharma Ahmedabad oncology facility concludes USFDA inspection with no observations
